TY - JOUR
T1 - Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation
T2 - A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial
AU - Knight, Jennifer M.
AU - Syrjala, Karen L.
AU - Majhail, Navneet S.
AU - Martens, Michael
AU - Le-Rademacher, Jennifer
AU - Logan, Brent R.
AU - Lee, Stephanie J.
AU - Jacobsen, Paul B.
AU - Wood, William A.
AU - Jim, Heather S.L.
AU - Wingard, John R.
AU - Horowitz, Mary M.
AU - Abidi, Muneer H.
AU - Fei, Mingwei
AU - Rawls, Laura
AU - Rizzo, J. Douglas
N1 - Funding Information:
Financial disclosure: Support for this study was provided by grant U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute . The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties. The second author (K.L.S.) was supported by a grant from the National Cancer Institute ( CA160684 ). The Center for International Blood and Marrow Transplantation is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI) , the National Heart, Lung and Blood Institute (NHLBI) , and the National Institute of Allergy and Infectious Diseases (NIAID) ; a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI ; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS) ; 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research ; and grants from Alexion ; * Amgen, Inc. ; anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US ; AstraZeneca ; Be the Match Foundation ; * Bluebird Bio, Inc. ; * Bristol Myers Squibb Oncology ; * Celgene Corporation ; Cellular Dynamics International, Inc. ; * Chimerix, Inc. ; Fred Hutchinson Cancer Research Center ; Gamida Cell Ltd. ; Genentech, Inc. ; Genzyme Corporation ; * Gilead Sciences, Inc. ; Health Research, Inc. Roswell Park Cancer Institute ; HistoGenetics, Inc. ; Incyte Corporation ; Janssen Scientific Affairs, LLC ; * Jazz Pharmaceuticals, Inc. ; Jeff Gordon Children's Foundation ; The Leukemia & Lymphoma Society ; Medac , GmbH ; MedImmune ; The Medical College of Wisconsin ; * Merck & Co, Inc. ; Mesoblast ; MesoScale Diagnostics, Inc. ; * Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Neovii Biotech NA, Inc. ; Novartis Pharmaceuticals Corporation ; Onyx Pharmaceuticals ; Optum Healthcare Solutions, Inc. ; Otsuka America Pharmaceutical, Inc. ; Otsuka Pharmaceutical Co, Ltd. – Japan ; PCORI ; Perkin Elmer, Inc. ; Pfizer, Inc ; * Sanofi US ; * Seattle Genetics ; * Spectrum Pharmaceuticals, Inc. ; St. Baldrick's Foundation ; * Sunesis Pharmaceuticals, Inc. ; Swedish Orphan Biovitrum, Inc. ; Takeda Oncology ; Telomere Diagnostics, Inc. ; University of Minnesota ; and * Wellpoint, Inc. This publication was also supported in part by the National Center for Advancing Translational Sciences , National Institutes of Health , through Grant Numbers UL1TR001436 and KL2TR001438 . The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the US Government.
Publisher Copyright:
© 2016 The American Society for Blood and Marrow Transplantation
PY - 2016/12/1
Y1 - 2016/12/1
N2 - This secondary analysis of a large, multicenter Blood and Marrow Transplant Clinical Trials Network randomized trial assessed whether patient-reported outcomes (PROs) and socioeconomic status (SES) before hematopoietic stem cell transplantation (HCT) are associated with each other and predictive of clinical outcomes, including time to hematopoietic recovery, acute graft-versus-host disease, hospitalization days, and overall survival (OS) among 646 allogeneic and autologous HCT recipients. Pretransplantation Cancer and Treatment Distress (CTXD), Pittsburgh Sleep Quality Index (PSQI), and mental and physical component scores of the Short-Form 36 were correlated with each other and with SES variables. PROs and SES variables were further evaluated as predictors of clinical outcomes, with the PSQI and CTXD evaluated as OS predictors (P < .01 considered significant given multiple testing). Lower attained education was associated with increased distress (P = .002), lower income was related to worse physical functioning (P = .005) and increased distress (P = .008), lack of employment before transplantation was associated with worse physical functioning (P < .01), and unmarried status was associated with worse sleep (P = .003). In this large heterogeneous cohort of HCT recipients, although PROs and SES variables were correlated at baseline, they were not associated with any clinical outcomes. Future research should focus on HCT recipients at greater psychosocial disadvantage.
AB - This secondary analysis of a large, multicenter Blood and Marrow Transplant Clinical Trials Network randomized trial assessed whether patient-reported outcomes (PROs) and socioeconomic status (SES) before hematopoietic stem cell transplantation (HCT) are associated with each other and predictive of clinical outcomes, including time to hematopoietic recovery, acute graft-versus-host disease, hospitalization days, and overall survival (OS) among 646 allogeneic and autologous HCT recipients. Pretransplantation Cancer and Treatment Distress (CTXD), Pittsburgh Sleep Quality Index (PSQI), and mental and physical component scores of the Short-Form 36 were correlated with each other and with SES variables. PROs and SES variables were further evaluated as predictors of clinical outcomes, with the PSQI and CTXD evaluated as OS predictors (P < .01 considered significant given multiple testing). Lower attained education was associated with increased distress (P = .002), lower income was related to worse physical functioning (P = .005) and increased distress (P = .008), lack of employment before transplantation was associated with worse physical functioning (P < .01), and unmarried status was associated with worse sleep (P = .003). In this large heterogeneous cohort of HCT recipients, although PROs and SES variables were correlated at baseline, they were not associated with any clinical outcomes. Future research should focus on HCT recipients at greater psychosocial disadvantage.
KW - Hematopoietic cell transplantation
KW - Hematopoietic recovery
KW - Patient-reported outcomes
KW - Quality of life
KW - Socioeconomic status
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84992110582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992110582&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.08.016
DO - 10.1016/j.bbmt.2016.08.016
M3 - Article
C2 - 27565521
AN - SCOPUS:84992110582
SN - 1083-8791
VL - 22
SP - 2256
EP - 2263
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -